Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-27

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Brilacidin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innovation Provides Update on U.S. Patent Applications Use of Brilacidin
    Innovation Provides Update on U.S. Patent Applications Use of Brilacidin

    21 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/21/2691932/0/en/Innovation-Pharmaceuticals-Provides-Update-on-U-S-Patent-Applications-Covering-Use-of-Brilacidin-in-Inflammatory-Bowel-Diseases-Coronaviruses-and-Fungal-Diseases.html

    GLOBENEWSWIRE
    21 Jun 2023
    Share Share
    Innovation Pharma Reports Vivo Antifungal Data Showing Brilacidin’s Potential
    Innovation Pharma Reports Vivo Antifungal Data Showing Brilacidin’s Potential

    13 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/13/2572586/0/en/Innovation-Pharmaceuticals-Reports-New-In-Vivo-Antifungal-Data-Showing-Brilacidin-s-Potential-for-Treating-Fungal-Keratitis.html

    GLOBENEWSWIRE
    13 Dec 2022
    Share Share
    Innovation Pharma Announces New Antiviral Research on Brilacidin
    Innovation Pharma Announces New Antiviral Research on Brilacidin

    28 Jun 2022

    // ACCESSWIRE

    https://www.accesswire.com/706735/Innovation-Pharmaceuticals-Announces-New-Antiviral-Research-on-Brilacidin-in-Bunyaviruses-and-Alphaviruses-to-be-Presented-at-the-2022-Military-Health-System-Research-Symposium

    ACCESSWIRE
    28 Jun 2022
    Share Share
    Innovation Pharma Reports Brilacidin Inhibits SARS-CoV-2 Variants
    Innovation Pharma Reports Brilacidin Inhibits SARS-CoV-2 Variants

    23 Jun 2022

    // ACCESSWIRE

    https://www.accesswire.com/706249/Innovation-Pharmaceuticals-Reports-Brilacidin-Inhibits-Omicron-Delta-Gamma-and-Alpha-SARS-CoV-2-Variants-Based-on-In-Vitro-Testing-by-NIHNIAID-Sponsored-and-Rutgers-University-Researchers

    ACCESSWIRE
    23 Jun 2022
    Share Share
    Database Lock Completed for Innovation's Phase 2 Trial of Brilacidin
    Database Lock Completed for Innovation's Phase 2 Trial of Brilacidin

    03 Nov 2021

    // YAHOOFINANCE

    https://finance.yahoo.com/news/database-lock-completed-innovation-pharmaceuticals-113000231.html

    YAHOOFINANCE
    03 Nov 2021
    Share Share
    Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2
    Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2

    18 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/18/2249692/0/en/Innovation-Pharma-Announces-New-Brilacidin-Antiviral-Research-on-Non-SARS-CoV-2-Endemic-Viral-Diseases-to-be-Presented-at-the-2021-Military-Health-System-Research-Symposium.html

    GLOBENEWSWIRE
    18 Jun 2021
    Share Share